Pharmaceuticals

Watson Pharmaceuticals Inc. (WPI) recently announced that it entered into a deal with India-based Natco Pharma Ltd. for the development and commercialization of a generic version of Celgene Corp.'s (CELG) Revlimid (lenalidomide) in the United States. Natco Pharma has filed an Abbreviated New...

Here is a quick peek at stocks that have abnormally high daily put/call ratios today relative to their average…. 1. Novartis AG (NYSE: NVS) 16,317 puts, 151 calls 2. Santander Finance Preferred (NYSE: STD) 3,813 puts, 395 calls 3. Popular Inc. (NASDAQ: BPOP) 39,144 puts, 4,816 calls 4. Gannett Co...

Cypress Bioscience, Inc. (NASDAQ: CYPB) today confirmed that it received a revised offer from Ramius LLC to acquire all of the outstanding common shares of Cypress common stock for $5.50 per share in cash that it does not already own. Cypress' Board of Directors, with the assistance of its...

By Josh Lipton Lei Wang has a unique perspective when it comes to investing in China: not only was the investment pro born, raised, and educated there, but he also used to work as an analyst at China's central bank. “I don't want to overstate it but, from my experience working for the central bank...

Watson Pharmaceuticals Inc. (WPI) recently announced that it entered into a deal with India-based Natco Pharma Ltd. for the development and commercialization of a generic version of Celgene Corp.'s (CELG) Revlimid (lenalidomide) in the United States. Natco Pharma has filed an Abbreviated New...

Recently, Novartis AG (NVS) presented data from a phase II study of its blood cancer pipeline drug LBH589 at the annual meeting of the American Society of Hematology (ASH). The phase II pivotal study showed sustained anticancer activity in extensively pretreated Hodgkin lymphoma patients who...

Wells Fargo is initiating coverage on Protalix BioTherapeutics, Inc. (AMEX: PLX) with an Outperform rating and a valuation range of $12-$14. “We believe regulatory approval of Protalix's lead drug taliglucerase, an enzyme replacement therapy for Gaucher disease partnered with Pfizer (PFE), is...

Ramius V&O Acquisition LLC, a subsidiary of Ramius LLC today announced that it has sent a letter to the Board of Directors of Cypress Bioscience, Inc. (Nasdaq: CYPB) outlining its willingness to acquire all of Cypress' outstanding Common Stock in a negotiated transaction for $5.50 per share.

Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin for the treatment of pulmonary arterial hypertension in regions where it is approved. In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

Based on FDA commentary, Jefferies believes that the question of whether to require pre-approval vs. post-approval CV safety studies for obesity remains a controversial topic of internal FDA debate. Current investor sentiment on Vivus (NASDAQ: VVUS) may not reflect the risk of a potential delay to...

Broadcom Corporation (NASDAQ: BRCM) was upgraded by Susquehanna from "neutral" to "positive." BRCM's shares closed at $45.91 yesterday. Broadcom's PEG ratio is 1.01. Citigroup upgrade Novo Nordisk A/S (NYSE: NVO) from "hold" to "buy." NVO's shares closed at $103.96 yesterday. Novo Nordisk's...

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Bayer's...

Analysts at Citigroup upgrade Novo Nordisk A/S (NYSE: NVO) from "hold" to "buy." NVO shares lost 0.75% to close at $103.96 yesterday. More Analyst Ratings here

California-based diagnostic products maker Gen-Probe Inc (GPRO) hassecured approval from the U.S. Food and Drug Administration (FDA) for its Prodesse ProAdeno+ assay for the detection of human adenovirus infection. The assay represents the latest addition to the company's Prodesse line of...